Spotlight on immuno-oncology

Immunotherapy is a huge area within oncology, which is having a significant impact on the way patients with certain malignancies are being treated. Combination therapies continue to show promise and other novel checkpoint inhibitors have led the field into an ever-increasing number of possible treatments. However, there are still numerous hurdles that need to be overcome to make this treatment modality an option for more treatment cancer types.

 

Read more

 


 

 

 

Spotlight on liquid biopsies

The field of liquid biopsy in cancer has generated significant interest over the past decade and this interest continues to build. It offers the potential to accurately isolate and analyze key biomarkers in a non-invasive way so cancer can be detected earlier, and treatment can be personalized to the patient. Join us as we explore the development of this field and the potential clinical applications of liquid biopsies in oncology.

 

Read more

 


 


Spotlight on organoids in oncology

Organoids have unearthed new avenues for the development of novel preclinical cancer models, which are essential for the efficient translation of basic cancer research into novel treatment regimens for patients with cancer. Join us as we explore how they can be utilized as an alternative model for cancer research.

 

Read more



Spotlight on tumor mutation burden

We have witnessed great advancements for cancer over the past few years, namely immunotherapy. Despite this success, the use of these drugs remains imprecise, with a limited ability to identify patients who will benefit from treatment. Tumor mutational burden (TMB) is promising as a predictive biomarker and could potentially lead the way for immuno-oncology to enter an era of precision medicine.

 

Read more



Spotlight on biosimilars in oncology

Over the coming weeks on Oncology Central we will be carrying out a Spotlight event exploring the field of biosimilars in oncology. Join us as we look further into their development, evaluate the potential benefits alongside regulatory challenges and see whether there are sufficient resources available to clinicians who are considering adopting biosimilars.

Read more



Spotlight on interventional oncology

Much of the available literature discussing the topic defines interventional oncology as the fourth pillar of cancer therapy, where it stands alongside medical, surgical and radiation oncology. Over the coming weeks on Oncology Central we will be carrying out a Spotlight event looking further into the field of interventional oncology. This Spotlight will take an overarching view and aim to review this discipline from benchside to bedside.

Read more



Spotlight on cancer and the immune system

Cancer immunotherapy is arguably one of the biggest developments and one of hottest topic within oncology. This Spotlight reviews the intricacies of how cancer cells and immune cells interact, look at the escape mechanisms that cancers employ to evade an antitumor immune response and explore the story behind some of the novel immunotherapy agents that have been developed to reverse this immune evasion.

Read more



Spotlight on circulating tumor cells

As has been proven, cancer does not simply consist of one type of cell; rather tumors can be made up of a heterogeneous collection of cells with varying phenotypes. It has been proposed that only a small subpopulation of the cells making up a tumor hold any tumorigenic potential – namely cancer stem cells (CSCs). The CSC model proposes that these cells renew and sustain the tumor in a background of nontumorigenic cells, driving therapy resistance, recurrence and enabling metastatic spread.

Read more



Spotlight on cancer stem cells

As has been proven, cancer does not simply consist of one type of cell; rather tumors can be made up of a heterogeneous collection of cells with varying phenotypes. It has been proposed that only a small subpopulation of the cells making up a tumor hold any tumorigenic potential – namely cancer stem cells (CSCs). The CSC model proposes that these cells renew and sustain the tumor in a background of nontumorigenic cells, driving therapy resistance, recurrence and enabling metastatic spread.

Read more